clinical trial · NCT05499013

Study to Assess SLN124 in Patients With Polycythemia Vera

$SLN →·phase2·active not recruiting·n = 69

Polycythemia VeraSLN124Placebo

brief summary

This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.

started

Jan 26, 2023

primary completion

Sep 1, 2026

completion

Mar 1, 2030

last updated

Dec 19, 2025

official title

Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol